ABSTRACT
OBJECTIVE: The aim of our study was to explore the expression of survivin gene in colorectal cancer (CRC) and its possibility as a molecular target for CRC chemoradiotherapy. MATERIALS AND METHODS: Immunohistochemistry was performed to detect the expression of survivin in 68 CRC specimens. The correlations between survivin expression and clinicopathological factors and prognosis were evaluated. RNA interference was employed to downregulate survivin expression. The effects of survivin downregulation on chemoradiotherapy of CRC cells were evaluated. RESULTS: The staining of survivin protein was strongly positive in the cytoplasm of CRC cells. Its expression was significantly correlated with tumor differentiation, Duke's stage, lymph node metastasis. Moreover, the elevated survivin expression was an independent factor for predicting the prognosis of CRC patients. Survivin downregulation could also enhance chemosensitivity or radiosensitivity of colorectal cells. CONCLUSIONS: Survivin might be an independent prognostic factor and a potential target for the chemoradiotherapy of CRC patients.
Subject(s)
Colonic Neoplasms/metabolism , Microtubule-Associated Proteins/metabolism , Neoplasm Proteins/metabolism , Rectal Neoplasms/metabolism , Adult , Aged , Apoptosis/physiology , Caspase 3/metabolism , Cell Line, Tumor , Cell Proliferation , Colonic Neoplasms/mortality , Colonic Neoplasms/therapy , Down-Regulation/physiology , Female , Humans , Immunohistochemistry , Inhibitor of Apoptosis Proteins , Kaplan-Meier Estimate , Male , Microtubule-Associated Proteins/drug effects , Microtubule-Associated Proteins/radiation effects , Middle Aged , Multivariate Analysis , Neoplasm Proteins/drug effects , Neoplasm Proteins/radiation effects , Prognosis , RNA, Small Interfering , Radiotherapy Dosage , Rectal Neoplasms/mortality , Rectal Neoplasms/therapy , Reverse Transcriptase Polymerase Chain Reaction , Survivin , Tumor Stem Cell AssayABSTRACT
The feasibility of chemotherapy for lymphatic metastatic gynecologic cancer via pelvic retroperitoneal cannulation was preliminarily studied. In 25 patients with gynecologic cancer 5-FU was safely allocated by cannulation to the pelvic retroperitoneal space including the external iliac, internal iliac, obturator, and deep inguinal and most of the common iliac lymph nodes. The 5-FU concentration in the lymph nodes on the injection side was 2-10 times that on the control side (P < 0.01). In 4 patients with nodal metastasis on the injection side, most cancer cells showed degeneration and necrosis. No severe complications or adverse effects were observed. The results suggested that the cannulation be used to treat the lymphatic metastasis of gynecologic cancer.
